Pharmaceutical Wastewater in Two Moves: CDFU First, CDOF for What Survives

Pharmaceutical wastewater has a reputation that is well earned. Its composition shifts constantly, its biodegradability is poor, it carries salinity and toxicity together, and because production runs in batches, both quality and volume move sharply. Conventional combinations of pre-treatment and biological stages struggle with the same four problems everywhere: the steps do not reinforce each other, shock resistance is weak, compliance is difficult to hold, and cost stays high.

Treating it as one problem is what causes those difficulties. Splitting it into two clearly defined jobs — pull the load out first, then attack what remains — changes the outcome.

Stage one: CDFU clears the load

SINOKLE CDFU (cyclonic dissolved-air flotation unit) sits at the front. It combines cyclonic shearing with micro-bubble dissolved air to generate ultra-fine micro-nano bubbles 5-20 μm in diameter. Those bubbles collide with mycelia, colloidal particles and macromolecular organics about three times as effectively as a conventional arrangement, and the suspended solids removal rate exceeds 95%.

The value of that step is not only the solids it removes. Every kilogram of impurity taken out up front is a kilogram that cannot blanket the catalyst surface and deactivate it, so catalyst service life extends by more than 30% and the oxidation stage keeps operating at its design rate instead of decaying quietly.

Stage two: CDOF opens rings and detoxifies

Behind the CDFU sits CDOF (integrated ozone advanced catalytic oxidation unit), built around a patent-protected catalyst that activates ozone at ambient temperature and pressure. The result is a rapid supply of hydroxyl radicals (·OH) with an oxidation potential as high as 2.8 V, which attack antibiotic residues, heterocyclic compounds, benzene series and other refractory pollutants without selectivity.

Measured performance shows the degradation rate for heterocyclic organics in chemically synthesised pharmaceutical wastewater reaching 85%-99%, while removal of residual antibiotics in biological fermentation wastewater exceeds 99%. Just as importantly, the oxidation lifts the B/C ratio, which is what converts a stream that biology cannot touch into one a biological stage can handle.

Holding steady when the batch changes

Volatile influent is the single biggest cause of instability in pharmaceutical plants, so the equipment has to tolerate wide ranges rather than a narrow design point. CDFU and CDOF units handle chemical synthesis, biological fermentation and formulation wastewater with COD between 5000-100000 mg/L, salinity up to 5% and pH anywhere from 3 to 11 — and they do it without a separate conditioning unit in front.

A PLC intelligent control system with online monitoring of COD, pH, ozone concentration and dissolved oxygen provides the second layer. When a batch pushes COD upward, the system adjusts ozone dosage, flotation operating pressure and wastewater residence time within about 30 minutes, which keeps effluent stable instead of letting one bad batch define the week.

Hardware is specified for the same reality. The equipment body is 316L stainless steel with an anti-corrosion coating, and internal flow channels are shaped for high-salinity, highly corrosive duty, with a service life beyond 10 years and none of the leakage or efficiency decay that corrosion causes in conventional designs.

Compliance now covers new pollutants too

With the Guideline on Available Techniques for Pollution Prevention and Control in the Pharmaceutical Industry and the Action Plan for the Management of New Pollutants in force, meeting conventional indicators is no longer sufficient — antibiotics and heterocyclic compounds are regulated in their own right.

On conventional indicators, effluent COD is held at 60-100 mg/L, ammonia nitrogen at ≤5 mg/L and colour removal at ≥90%, satisfying GB 21904-2008 for chemical synthesis products and the tighter local upgrading targets that many provinces apply.

On new pollutants, hydroxyl radicals degrade sulfonamide, quinolone and cephalosporin antibiotics at rates exceeding 99%, leaving residuals far below the control limits in the List of Priority Controlled Chemicals, while toxic intermediates such as halogenated organics and nitro compounds are decomposed with a toxicity removal rate above 85%. There is no secondary pollution to manage either: ozone breaks down into oxygen with no harmful gas emission, and sludge generation falls by 60%-70% compared with conventional processes, which removes the sludge disposal burden entirely.

Footprint, ozone efficiency and maintenance

Skid-mounted integration is what makes the process attractive on a constrained site. The package occupies only 40%-50% of the floor area of a conventional split layout, requires no complex piping or civil works, installs in 15-30 days and cuts initial investment by 20%-30%.

Operating economics are driven mostly by ozone utilisation. The dedicated catalyst raises utilisation to over 85% where conventional ozone processes reach only 40%-60%, and the OC ratio — ozone dosage against COD — stays at ≤1, so chemical consumption drops by 30%-40%. Automation exceeds 95%, meaning no dedicated attendance is required; the catalyst needs periodic inspection and replacement every 3-5 years, which leaves O&M costs at 60%-70% of a conventional process.

The same hardware serves three different roles. It can act as the core treatment unit for direct compliant discharge, as a pre-treatment step to raise biodegradability before a biological stage, or as an advanced treatment unit for effluent upgrading. A single standard skid suits a small pharmaceutical manufacturer, while several modules in parallel cover a large pharmaceutical park.